Figure 3From: Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's diseaseReceiver operator characteristic-area under the curveanalyses. The ratio between true and false positive discovery rates are shown in (A) Crohn's disease and (B) rheumatoid arthritis with the gene panels demonstrating an accuracy in differentiating between responder and non-responder patients of over 90%. CV stands for the success of cross-validation.Back to article page